Chair of Sernova Biotherapeutics Resigns
Sernova Biotherapeutics (SEOVF), a regenerative medicine company developing Cell Pouch Bio-hybrid Organ for type 1 diabetes treatment, announced the resignation of its Board Chair, Ross Haghighat. The resignation was tendered on May 24th, 2025, and accepted by Sernova's Board of Directors. The company expressed gratitude for Haghighat's leadership and extended well wishes for his future endeavors.
Sernova Biotherapeutics (SEOVF), un'azienda di medicina rigenerativa che sviluppa l'Organo Bio-ibrido Cell Pouch per il trattamento del diabete di tipo 1, ha annunciato le dimissioni del suo Presidente del Consiglio, Ross Haghighat. Le dimissioni sono state presentate il 24 maggio 2025 e accettate dal Consiglio di Amministrazione di Sernova. L'azienda ha espresso gratitudine per la leadership di Haghighat e gli ha augurato il meglio per i suoi futuri progetti.
Sernova Biotherapeutics (SEOVF), una compañía de medicina regenerativa que desarrolla el Órgano Biohíbrido Cell Pouch para el tratamiento de la diabetes tipo 1, anunció la renuncia de su presidente de la junta, Ross Haghighat. La renuncia fue presentada el 24 de mayo de 2025 y aceptada por el Consejo de Administración de Sernova. La compañía expresó su agradecimiento por el liderazgo de Haghighat y le deseó éxito en sus futuros proyectos.
Sernova Biotherapeutics (SEOVF)는 제1형 당뇨병 치료를 위한 셀 파우치 바이오-하이브리드 장기 개발에 주력하는 재생 의학 회사로, 이사회의 의장 Ross Haghighat의 사임을 발표했습니다. 사임은 2025년 5월 24일에 제출되었으며, Sernova 이사회에서 수락되었습니다. 회사는 Haghighat 의장의 리더십에 감사를 표하며 그의 앞날에 행운을 빌었습니다.
Sernova Biotherapeutics (SEOVF), une entreprise de médecine régénérative développant l'organe bio-hybride Cell Pouch pour le traitement du diabète de type 1, a annoncé la démission de son président du conseil d'administration, Ross Haghighat. La démission a été soumise le 24 mai 2025 et acceptée par le conseil d'administration de Sernova. La société a exprimé sa gratitude pour le leadership de Haghighat et lui a souhaité le meilleur pour ses projets futurs.
Sernova Biotherapeutics (SEOVF), ein Unternehmen für regenerative Medizin, das das Cell Pouch Bio-hybrid Organ zur Behandlung von Typ-1-Diabetes entwickelt, gab den Rücktritt seines Vorstandsvorsitzenden, Ross Haghighat, bekannt. Der Rücktritt wurde am 24. Mai 2025 eingereicht und vom Vorstand von Sernova akzeptiert. Das Unternehmen dankte Haghighat für seine Führung und wünschte ihm alles Gute für seine zukünftigen Vorhaben.
- None.
- Unexpected departure of Board Chair could create leadership uncertainty
- Timing and immediate acceptance of resignation might suggest potential internal challenges
LONDON, Ontario and BOSTON, May 26, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced the resignation of its Chair.
Mr. Ross Haghighat tendered his resignation on May 24th and it was accepted by the Sernova Board. The Board of Directors of Sernova thanks Ross for his service as a trusted leader and sincerely wishes him luck in the future.
ABOUT SERNOVA BIOTHERAPEUTICS
Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem-cell derived islet like clusters in collaboration with Evotec to create Bio-hybrid Organs to treat T1D. A Bio-hybrid Organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on T1D and thyroid disorders.
FOR FURTHER INFORMATION, PLEASE CONTACT:
David Burke VP, Investor Relations (917) 751-5713 Email: David.Burke@sernova.com Website: https://sernova.com/
The TSX has not reviewed this news release and does not accept responsibility for the accuracy or adequacy of this news release.
FAQ
Who resigned as Chair of Sernova Biotherapeutics (SEOVF) in May 2025?
What is Sernova Biotherapeutics' (SEOVF) main product focus?
When did Ross Haghighat's resignation from Sernova become effective?
What stock exchanges is Sernova Biotherapeutics listed on?
